Plant Name: Kadsura interior
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.306E-09 | 5.303E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 4.658E-08 | 1.857E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.134E-07 | 2.398E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.212E-07 | 2.398E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 6.237E-07 | 9.053E-04 | ABCC1, AKR1B1, AKR1B10, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.248E-06 | 1.404E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 1.720E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.054E-06 | 2.463E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.054E-06 | 2.463E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.054E-06 | 2.463E-03 | GPBAR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 4.179E-06 | 3.250E-03 | AKR1B1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 6.104E-06 | 4.027E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 4.027E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 4.027E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 6.714E-06 | 4.300E-03 | AKR1B10, CYP1A2, CYP1B1, CYP3A4, PLA2G1B |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.209E-06 | 4.831E-03 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.017E-05 | 5.676E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.524E-05 | 7.745E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.524E-05 | 7.745E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0051716; cellular response to stimulus | 1.530E-05 | 7.745E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, NR1H4, PLA2G1B, POLB, PTPN1, PTPRF, RECQL, RORC |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.697E-05 | 8.396E-03 | NR1H4, PTPN1, PTPN2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.981E-05 | 9.377E-03 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.132E-05 | 9.673E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 2.283E-05 | 9.919E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, NR1H4, PLA2G1B, POLB, RORC |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.578E-09 | 1.083E-07 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.373E-09 | 1.758E-07 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.512E-08 | 2.117E-07 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.252E-06 | 6.931E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.073E-06 | 3.227E-05 | PLA2G1B; CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.590E-05 | 2.513E-04 | CYP1A2; CYP1A1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.305E-04 | 6.851E-04 | HSD11B1; AKR1B10; PLA2G1B; CYP1A2; CYP1A1; AKR1B1; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.298E-05 | 3.179E-04 | PTPN1; ACP1; PTPRF |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.131E-03 | 3.958E-03 | CYP1A1; CYP1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 5.864E-04 | 2.239E-03 | AKR1B10; AKR1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.571E-03 | 5.075E-03 | AKR1B10; AKR1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.064E-04 | 1.896E-03 | AKR1B10; AKR1B1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.064E-03 | 8.044E-03 | ABCC1; CYP1B1; CDC25B |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.141E-03 | 6.343E-03 | CYP1A2; CYP3A4 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 4.628E-04 | 1.944E-03 | AKR1B10; AKR1B1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.265E-03 | 6.343E-03 | NR1H4; CYP3A4 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.245E-03 | 1.224E-02 | PTPN1; PTPRF |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 8.394E-03 | 1.856E-02 | PTPN1; PTPRF |
| hsa04977 | Vitamin digestion and absorption_Homo sapiens_hsa04977 | 2.374E-02 | 4.943E-02 | ABCC1 |
| hsa00592 | alpha-Linolenic acid metabolism_Homo sapiens_hsa00592 | 2.472E-02 | 4.943E-02 | PLA2G1B |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.991E-03 | 1.224E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDC25B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B; AKR1B1 |